Author

D.-I. Balourdas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. C. Joerger· 5 shared L. M. Berger· 4 shared S. Knapp· 4 shared A. Kraemer· 3 shared B.-T. Berger· 3 shared L. Elson· 3 shared T. Hanke· 3 shared A. Kaiser· 2 shared

Activity by Year

2023-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBiochemistry

A. C. Joerger

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Development of selective pyridopyrimidin-7(8H)-one-based Mammalian STE20-like (MST3/4) kinase inhibitors

M. Rak, A. Menge, R. Tesch, L. M. Berger, D.-I. Balourdas, E. Shevchenko, A. Kraemer, L. Elson, B.-T. Berger, I. Abdi, L. M. Wahl, A. Poso, A. Kaiser, T. Hanke, T. Kronenberger, , S. Knapp

This study develops selective MST3/4 kinase inhibitors and demonstrates their distinct cellular effects compared to MST1/2 inhibition.

bioRxiv · Nov 24, 2023Biochemistry

Synthesis of pyrazole-based macrocycles leads to a highly selective inhibitor for MST3

J. A. Amrhein, L. M. Berger, D.-I. Balourdas, A. C. Joerger, A. Menge, A. Kraemer, J. M. Frischkorn, B.-T. Berger, L. Elson, A. Kaiser, M. Schubert-Zsilavecz, S. Mueller, S. Knapp, T. Hanke

The paper designs and synthesizes a macrocyclic inhibitor, JA310, that selectively targets MST3 with high potency and kinome-wide selectivity.

bioRxiv · Oct 20, 2023Biochemistry

Development of potent dual BET/HDAC inhibitors via pharmacophore merging and structure-guided optimization

N. Bauer, D.-I. Balourdas, J. R. Schneider, X. Zhang, L. M. Berger, B.-T. Berger, N. A. Klopp, J. T. Siveke, S. Knapp, A. C. Joerger

This study develops potent dual BET/HDAC inhibitors through pharmacophore merging and structure-guided optimization, showing improved potency and efficacy in cancer cell models.

bioRxiv · Jul 18, 2023 · PreprintBiochemistry

Shifting the selectivity of pyridopyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

M. Rak, R. Tesch, L. M. Berger, E. Shevchenko, M. Raab, A. Tjaden, R. Zhubi, D.-I. Balourdas, A. C. Joerger, A. Poso, A. Kraemer, L. Elson, A. Lucic, T. Kronenberger, T. Hanke, , S. Knapp

This paper develops a selective SIK kinase inhibitor, MR22, by optimizing a pyrido[2,3-d]pyrimidin-7(8H)-one scaffold to eliminate PAK activity, demonstrating its efficacy in ovarian cancer cells.

European Journal of Medicinal Chemistry · Jun 1, 2023Peer-reviewedBiochemistry

Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis

J. Funk, M. Klimovich, E. Pavlakis, M. Neumann, D. Drangenstein, M. Noeparast, P. Hunold, A. Borowek, D.-I. Balourdas, K. Kochan, N. Merle, I. Bullwinkel, M. Wanzel, S. Elmshauser, A. Nist, , T. Stiewe

This study uses CRISPR mutagenesis to analyze the functional impact of TP53 mutations across 9,225 variants, revealing their effects on tumor cell fitness and metastasis.

bioRxiv · Mar 10, 2023Cancer Biology